Abstract
Hepatocyte transporters control the hepatobiliary elimination of many drugs, metabolites and endogenous substances. Hepatocyte transporter function is altered in several pathophysiological situations and can be modulated by certain drugs, with a potential impact for pharmacokinetics and drug-induced liver injury. Development of substrate probes with optimal properties for selective and quantitative imaging of hepatic transporters remains a challenge. [99mTc]mebrofenin has been used for decades for hepatobiliary scintigraphy, but the specific transporters controlling its liver kinetics have been characterized more recently. These include sinusoidal influx transporters (organic anion-transporting polypeptides, OATP) responsible for hepatic uptake of [99mTc]mebrofenin, and efflux transporters (multidrug resistance-associated proteins, MRP) mediating its canalicular (liver-to-bile) and sinusoidal (liver-to-blood) excretion. Pharmacokinetic modeling enables molecular interpretation of [99mTc]mebrofenin scintigraphy data, thus offering a widely available translational method to investigate transporter-mediated drug-drug interactions in vivo. [99mTc]mebrofenin allows for phenotyping transporter activity at the different poles of hepatocytes as a biomarker of liver function.
- Hepatology
- Molecular Imaging
- Radiotracer Tissue Kinetics
- ATP-binding cassette transporter,
- Liver function
- Mebrofenin
- Pharmacokinetics
- Solute carrier transporter
- Copyright © 2021 by the Society of Nuclear Medicine and Molecular Imaging, Inc.